Fig. 3
From: [68 Ga]Ga-FAPI-04 PET/CT may be a predictor for early treatment response in rheumatoid arthritis
Representative [68 Ga]Ga-FAPI-04 and [18F]FDG PET/CT images of non-responders at 3-months’ follow-up based on CDAI and SDAI response criteria. Patient# 13 was a 64-year-old woman with 3 affected joints detected in PET/CT (PJCFAPI = 3, TSUFAPI = 27.7 SUV bw*ml, MSVFAPI = 9.2 mL, TSUFDG = 4.3 SUV bw*ml, MSVFDG = 1.5 mL). She was treated with methotrexate and etanercept. The CDAI and SDAI decreased 4.4% and 1.6% respectively from baseline at 3-months’ follow up. In patient# 14 (56-year-old man), [68 Ga]Ga-FAPI-04 PET/CT showed 15 affected joints (PJCFAPI = 15, TSUFAPI = 44.0 SUV bw*ml, MSVFAPI = 15.1 mL, TSUFDG = 47.5 SUV bw*ml, MSVFDG = 16.3 mL). The CDAI and SDAI decreased 40.0% and 30.6% from baseline after 3 months treating with prednisone, Tripterygium wilfordii and ibuprofen (change to methotrexate and adalimumab later). ESR Erythrocyte sedimentation rate, CRP C-reactive protein, TJC Tender joint count, SJC Swollen joint count, CDAI Clinical Disease Activity Index, SDAI Simplified Disease Activity Index, DAS28 Disease Activity Score with 28-joint counts, PJC PET joint count, TSU Total synovitis uptake, MSV Metabolic synovitis volume